Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E144.96 EPS (ttm)2.95 Insider Own1.10% Shs Outstand101.67M Perf Week2.69%
Market Cap43.48B Forward P/E36.31 EPS next Y11.78 Insider Trans10.88% Shs Float74.68M Perf Month2.98%
Income334.70M PEG7.17 EPS next Q2.75 Inst Own72.70% Short Float5.23% Perf Quarter18.82%
Sales2.63B P/S16.55 EPS this Y-43.60% Inst Trans-2.68% Short Ratio4.72 Perf Half Y52.61%
Book/sh25.32 P/B16.89 EPS next Y18.42% ROA10.00% Target Price404.30 Perf Year58.06%
Cash/sh10.25 P/C41.71 EPS next 5Y20.21% ROE14.70% 52W Range262.97 - 437.64 Perf YTD55.37%
Dividend- P/FCF80.93 EPS past 5Y42.20% ROI19.20% 52W High-2.28% Beta0.84
Dividend %- Quick Ratio5.10 Sales past 5Y54.60% Gross Margin87.70% 52W Low62.62% ATR12.24
Employees2714 Current Ratio5.40 Sales Q/Q21.60% Oper. Margin30.60% RSI (14)58.38 Volatility4.33% 2.73%
OptionableYes Debt/Eq0.22 EPS Q/Q-44.00% Profit Margin12.70% Rel Volume1.64 Prev Close423.79
ShortableYes LT Debt/Eq0.22 EarningsNov 04 BMO Payout0.00% Avg Volume827.52K Price427.64
Recom2.00 SMA202.67% SMA508.30% SMA20026.78% Volume1,355,024 Change0.91%
Nov-20-14Reiterated Brean Capital Buy $390 → $450
Nov-19-14Reiterated ROTH Capital Buy $422 → $461
Nov-11-14Reiterated Argus Buy $375 → $430
Nov-05-14Reiterated RBC Capital Mkts Outperform $373 → $410
Oct-24-14Reiterated Canaccord Genuity Buy $350 → $460
Sep-02-14Reiterated Brean Capital Buy $380 → $390
Aug-06-14Reiterated RBC Capital Mkts Outperform $349 → $373
Jul-21-14Initiated Argus Buy $375
Apr-16-14Initiated Canaccord Genuity Buy $350
Feb-13-14Downgrade Oppenheimer Outperform → Perform $310 → $325
Sep-30-13Reiterated Oppenheimer Outperform $300 → $310
Aug-22-13Initiated Oppenheimer Outperform $300
May-17-13Initiated UBS Neutral $290
May-06-13Reiterated RBC Capital Mkts Outperform $270 → $286
May-06-13Reiterated Barclays Overweight $275 → $305
May-02-13Reiterated Barclays Overweight $194 → $275
Feb-28-13Initiated Barclays Overweight $194
Dec-21-12Reiterated RBC Capital Mkts Outperform $171 → $190
Feb-14-12Reiterated RBC Capital Mkts Outperform $83 → $130
Jan-10-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
Dec-19-14 10:46AM  Cramer: Downside to Biotech as ImmunoGen Stock Cut in Half at TheStreet
09:24AM  Cramer's Mad Dash: Tale of two biotechs CNBC
Dec-18-14 08:10PM  Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally at TheStreet
06:33PM  Cramer: Watch out Regeneron, here comes Isis at CNBC
06:13PM  Cramer's perfect recipe for a Santa Claus rally at CNBC
Dec-17-14 07:00PM  Cramer: Here's what the Fed did today CNBC
06:57PM  Lightning Round: Good stock with a good yield at CNBC
Dec-15-14 02:53PM  Stocks Hit By More Selling; S&P 500 Gives Up 50-Day Line at Investor's Business Daily
08:00AM  Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol PR Newswire
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
01:12PM  Midday movers: McDonald's, Sony, Celgene & more at CNBC
Dec-05-14 12:18PM  Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences at TheStreet
Dec-04-14 06:50PM  Lightning Round: Time to buy buy buy for 2015 at CNBC
09:40AM  Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015 at 24/7 Wall St.
08:15AM  Regeneron at 52-Week High on Eylea Priority Review Status Zacks
Dec-03-14 12:29PM  Jim Cramer on the Stock Market: You Have to Love Biotech at TheStreet
09:51AM  Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Zacks
08:50AM  Stock Market News for December 03, 2014 Zacks
06:00AM  Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES at TheStreet
Dec-02-14 08:21PM  Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners at TheStreet
07:00PM  Cramer: One of the best stocks to own now CNBC
06:33PM  Cramer's heated love affair with biotech at CNBC
06:00PM  Cramer: Stocks you shouldn't chase CNBC
04:20PM  Regeneron/Bayer's Eylea to be Reviewed on a Priority Basis Zacks
11:27AM  Cramer: Cypress Semiconductor Merger With Spansion Is Fantastic at TheStreet
11:11AM  Jim Cramer's Five Best Stock Picks for the Biotech Sector at TheStreet
Dec-01-14 07:00AM  EYLEA┬« (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema PR Newswire
Nov-28-14 10:30AM  Insider Trading Alert - ALJ, REGN And PRSC Traded By Insiders at TheStreet
Nov-26-14 04:13PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Nov-25-14 11:07AM  Cramer: Workday, Netflix, Amazon Struggle as Momentum Lags at TheStreet
06:00AM  Jim Cramer's Top Stock Picks: CSCO LB REGN AAPL YHOO at TheStreet
Nov-24-14 08:22PM  Jim Cramer's 'Mad Money' Recap: Here's Where Money Managers Should Put Their Money at TheStreet
07:08PM  Cramer Remix: This industry isn't dead yet! at CNBC
06:40PM  Cramer: Not too late to buy Regeneron CNBC
Nov-21-14 04:23PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
10:24AM  UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts Benzinga
10:03AM  Fighting kids' cancer, one voucher at a time at CNBC
Nov-20-14 03:30PM  Regeneron & Sanofi Present Positive Data on PCSK9 Drug Zacks
03:27PM  Gilead to Buy Knight Therapeutics' Priority Review Voucher Zacks
12:31PM  Regeneron Shares Could Reach $450 at Barrons.com
11:44AM  Sanofi's Bullish Pipeline Forecast Underwhelms Street at Investor's Business Daily
08:31AM  Sanofi eyes more than $38 bln from new drugs after CEO exit Reuters
08:00AM  The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Zacks
01:47AM  Sanofi, Regeneron eczema drug gets FDA fast-track designation Reuters
01:30AM  Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis PR Newswire
Nov-19-14 05:01PM  The Forbes Healthcare Summit 2014: The Agenda at Forbes
03:30PM  Regeneron/Bayer's Eylea Gets Japanese Approval for DME Zacks
12:16PM  3 Drugs Stocks Driving The Industry Higher at TheStreet
11:07AM  Stocks Boosted by Merck's Vytorin Data at Barrons.com
10:23AM  Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Zacks
08:15AM  Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol PR Newswire
08:15AM  Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol PR Newswire
Nov-18-14 04:41PM  Health Care dominates the Lg Cap All-Time Highs today... Yahoo Finance Blogs
11:46AM  Gilead Sciences: Harvoni Gets European Marketing OK at Barrons.com
06:00AM  Jim Cramer's Top Stock Picks: REGN CST MPC LULU at TheStreet
03:05AM  Regeneron Announces EYLEA┬« (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan PR Newswire
Nov-17-14 07:11PM  Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us at TheStreet
01:41PM  Long-Awaited Study Boosts Merck, Could Be Good News for Regeneron, Amgen at Barrons.com
01:35PM  Merck Drug Works: Vytorin Study Proves Successful at Investor's Business Daily
11:45AM  Surprise! Vytorin Works. Here Are Five Things You Should Know. at Forbes
11:32AM  IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe at Forbes
08:39AM  After Years Under Attack, Merck's Vytorin Proves Effective at Forbes
Nov-13-14 10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
08:02AM  Meet 5 U.S. Techs, Biotechs With Strong Fundamentals at Investor's Business Daily
07:36AM  The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead Zacks
Nov-12-14 12:25PM  3 Stocks Moving The Drugs Industry Upward at TheStreet
10:00AM  Regeneron/Sanofi Announce Positive Dupilumab Study Data Zacks
07:48AM  Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy Zacks
Nov-11-14 06:05PM  Cramer spotlight: These three sectors keep growing at CNBC
06:00PM  Cramer: Tuesday all about consolidation CNBC
04:28PM  Dow, S&P Creep Higher; Close at New Record at Barrons.com
01:53PM  On the Move: Vodafone Up 5.2%; Regeneron Climbs 3.3%; ICU Medical Gains 14%; Isis Up 9% at Barrons.com
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
09:51AM  Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) at TheStreet
03:39AM  Sanofi's dual-action biotech asthma drug performs well in test Reuters
01:00AM  Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma PR Newswire
Nov-07-14 08:35AM  What You Need To Know About IMPROVE-IT at Forbes
Nov-06-14 07:08PM  10-Q for Regeneron Pharmaceuticals, Inc. Company Spotlight
09:32AM  France asks Roche for data on use of cancer drug Avastin in eye Reuters
Nov-05-14 08:46AM  Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold Zacks
Nov-04-14 07:02PM  Jazz Q3 Tops On Defitelio But Regeneron Cuts View Investor's Business Daily -5.79%
06:09PM  Today's Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
04:16PM  Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
03:30PM  Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance Zacks
02:06PM  US STOCKS-Wall St slips as energy extends recent slide Reuters
12:52PM  Regeneron falls after paring Eylea sales outlook AP
12:02PM  Regeneron cuts top end of eye drug sales forecast Reuters
11:19AM  US STOCKS-Energy shares lead Wall St lower in broad decline Reuters
11:15AM  Regeneron skids on shortfall in Eylea sales at MarketWatch
11:10AM  Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue Guidance at TheStreet
10:51AM  Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter at Investor's Business Daily
10:39AM  Regeneron: That Was Disappointing at Barrons.com
10:32AM  Stocks Tightly Mixed After Open; Alibaba Climbs On Q2 Results at Investor's Business Daily
10:15AM  US STOCKS-Energy shares lead Wall St lower, indexes near records Reuters
09:29AM  Cramer: Today wake-up call for Nasdaq stocks CNBC
08:52AM  US STOCKS-Futures point to lower open, energy shares in view Reuters
07:07AM  Q3 2014 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:55AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
06:47AM  Regeneron third-quarter revenue rises on strong Eylea sales Reuters
06:30AM  Regeneron Reports Third Quarter 2014 Financial and Operating Results PR Newswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM